Arcxis Biotechnologies® Announces Release of First Commercial Product for Molecular Analysis

Share Article

Arcxis Biotechnologies® announces the launch of ArcPure™ viral DNA and viral RNA sample preparation kits for life science and clinical laboratories.

We were inspired to develop the ArcPure spin-column technology based on the superior performance of Xisyl™, our pre-market automated sample preparation system

Arcxis Biotechnologies is pleased to announce the availability of their first commercial product line: the ArcPure™ line of nucleic acid isolation and purification kits. These sample preparation kits are optimized to extract and purify viral DNA and RNA from plasma and whole blood. The ArcPure kits are designed to increase downstream assay sensitivity, a critical component of the molecular analytical process. In addition, the product line offers an exceptionally cost effective approach to efficient and expeditious extraction, purification and concentration of nucleic acids using standard laboratory equipment.

The ArcPure line leverages components of the company's patented automated molecular system technologies, currently under development. As such, the kits offer technologists and investigators cutting edge performance in a familiar format, at a significantly lower cost than standard commercially available products. "We were inspired to develop the ArcPure spin-column technology based on the superior performance of Xisyl™, our pre-market automated sample preparation system", commented Arcxis Biotechnologies CEO, Chris Meda. "We are proud of the superior quality of the kits and pleased to offer a robust, cost-effective option to researchers and clinical laboratorians alike."

The ArcPure Sample Preparation kits will initially be available for purchase via the Arcxis e-commerce site, beginning October first.

About Arcxis:
Led by a seasoned team with decades of success in research & development, commercialization and market insight, Arcxis Biotechnologies is focused on developing elegant and cost-effective solutions to today's molecular diagnostic challenges. Incorporated in November 2004, the company holds numerous patents and currently supports its advances in molecular sample processing, target detection, microfluidics and workflow automation with both venture funds (Claremont Creek Ventures, Kaiser Permanente Ventures, Alafi Capial, In-Q-Tel) and cohesive collaborations with leading industry and academic organizations.

For more information about Arcxis Biotechnologies or to order ArcPure Sample Preparation kits, visit: http://www.arcxis.com/.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Visit website